🏦 In re Gritstone bio, Inc. Securities Litigation Settlement

Lead Plaintiff alleged that Gritstone bio's former CEO violated the federal securities laws by making materially false and misleading statements about Gritstone's current Good Manufacturing Practices (cGMP) compliance, its ability to satisfy its contract with the Biomedical Advanced Research and Development Authority (BARDA), and the timeline for launching the CORAL Phase 2b clinical trial, artificially inflating the price of Gritstone securities.

All persons who purchased publicly traded Gritstone bio, Inc. securities between March 9, 2023 and April 2, 2024, both dates inclusive, and were damaged thereby.

Pro rata share of a $6,000,000 cash settlement fund under the Court-approved Plan of Allocation; Lead Plaintiff's damages expert estimates an average recovery of approximately $0.11 per share if all approximately 54.9 million allegedly damaged shares participate, before fees, expenses and costs

November 13, 2026

October 2, 2026

In re Gritstone bio, Inc. Securities Litigation, Case No. 3:24-cv-03640-CRB, U.S. District Court for the Northern District of California (San Francisco Division). Stipulation of Settlement dated May 15, 2026; the proposed $6,000,000 cash settlement resolves the action against Gritstone's former CEO, who denies all allegations of fault, liability or wrongdoing. Claim Forms must be submitted online or postmarked no later than November 13, 2026, which is also the deadline to request exclusion and to object; the Settlement Fairness Hearing is set for December 4, 2026 at 10:00 a.m. Claims administrator: Strategic Claims Services; court-appointed Lead Plaintiff is Richard Rodriguez, and the notice caption for the action is In re Gritstone bio, Inc. Securities Litigation.